Lyka Labs Ltd

LYKALABS

Watchlist

AI Mode

‌

Market Cap

₹ 276 Cr

P/E

135.61

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

OVERVALUED

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products.

The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India.

Post-2016, Lyka merged its subsidiaries, bolstering its focus on domestic markets and ethical products.

Significant equity acquisition by IPCA and partners in 2021-22 established them as joint promoters, signaling strategic alignment.

In 2023, Lyka acquired the animal healthcare business of Agilis Healthcare, enhancing its veterinary portfolio.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

276 Cr

Volatility

Moderate Risk

P/E Ratio

135.6

Industry P/E

30.8

PEG Ratio

0.3

P/B Ratio

2.7

52W High

167.10

52W Low

73.56

Sales CAGR

24.56%

-6.42%

27.02%

10Y

9.25%

Profit CAGR

402.67%

-40.92%

—

10Y

6.12%

ROE

TTM

2.03%

-3.54%

9.59%

10Y

-17.08%

ROCE

TTM

4.68%

4.37%

18.05%

10Y

7.03%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
TLL	300.00	351 Cr	19.63	4.19	0.00	22.08	17.36	7.60
ZIMLAB	71.00	346 Cr	52.62	1.38	0.00	2.62	6.18	1.41
BROOKS	97.00	287 Cr	20.58	2.48	0.00	12.08	12.32	9.98
LYKALABS	77.30	276 Cr	135.61	2.73	0.00	2.03	4.68	1.50
AMBASARABH	29.09	223 Cr	14.26	1.51	0.00	10.60	10.22	3.70
SYSCHEM	48.55	210 Cr	46.49	2.22	0.00	4.78	5.68	2.49
NATCAPSUQ	186.00	192 Cr	—	0.85	0.00	-4.87	-1.11	-2.84

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	23	28	33	28	30	41	34	33	33	37
Expenses	20	24	26	26	26	36	29	29	29	39
Operating Profit	2.65	4.18	6.86	2.03	3.71	4.95	5.19	4.09	3.69	-2.54
OPM %	11.58	14.93	21.07	7.31	12.32	12.03	15.36	12.23	11.17	-6.93
Other Income	0.38	-0.18	0.54	0.31	0.56	0.03	0.83	0.82	0.63	1.09
Interest	1.35	1.19	1.28	1.07	0.65	0.54	0.61	0.47	0.85	0.79
Depreciation	3.47	3.59	2.84	2.90	1.76	1.76	1.83	1.42	2.11	2.15
Profit Before Tax	-1.71	-0.66	3.05	-1.67	2.01	2.86	3.58	3.02	1.35	-4.38
Tax %	-7.60	27.27	41.64	-27.54	28.36	26.57	24.30	32.78	26.67	26.71
Net Profit	-1.85	-0.49	1.78	-2.13	1.44	2.10	2.71	2.03	1.00	-3.21
EPS in Rs	-0.53	-0.14	0.49	-3.55	0.40	0.58	0.75	0.49	0.25	-0.94

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	117	61	71	61	86	194	93	111	138	141
Expenses	87	63	73	65	67	93	76	95	121	124
Operating Profit	29	-2.74	-1.90	-3.67	20	101	17	16	18	18
OPM %	25.19	-4.52	-2.68	-5.97	22.82	52.12	18.09	14.13	12.95	12.67
Other Income	-1.90	4.37	0.95	-30	0.43	-4.42	-3.99	1.04	2.23	2.31
Interest	19	9.58	7.17	20	26	20	12	4.89	2.27	2.47
Depreciation	10	11	7.31	8.01	8.32	17	14	13	6.77	7.12
Profit Before Tax	-8.10	-20	-15	-62	-14	59	-13	-0.93	11	11
Tax %	18.59	5.19	58.82	-1.20	28.66	35.11	0.14	-180.63	28.69	27.47
Net Profit	-6.60	-19	-6.35	-63	-10	38	-13	-2.62	7.93	7.84
EPS in Rs	-1.35	—	—	-18.02	-3.26	10.89	-3.78	-3.73	2.22	0.55
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	22	22	28	28	29	29	29	31	33	—
Reserves	22	16	21	15	-43	-54	-15	15	35	68
Borrowings	86	86	51	96	141	163	130	75	59	39
Other Liabilities	111	128	129	77	74	53	42	31	30	69
Total Liabilities	242	252	229	216	200	190	186	152	157	176
Fixed Assets	104	133	116	108	105	98	94	68	58	85
CWIP	30	24	28	31	28	26	18	16	23	1.20
Investments	0.39	0.26	0.23	0.02	0.02	0.02	0.02	0.05	0.09	0.04
Other Assets	107	94	85	77	68	66	74	67	76	90
Total Assets	242	252	229	216	200	190	186	152	157	176

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	12	31	11	27	5.32	8.81	79	8.95	1.77	1.90
Cash from Investing Activity	17	-13	-3.17	-3.97	-0.11	-0.16	-6.17	7.35	-9.49	-12
Cash from Financing Activity	-30	-19	-10	-23	3.38	-12	-63	-22	1.95	5.29
Net Cash Flow	-0.96	-0.43	-2.69	-0.72	8.60	-3.15	9.90	-5.34	-5.76	-4.60

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Apr 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Apr 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	54.56%	54.58%	54.81%	54.81%	54.81%	58.10%	58.10%	58.10%	58.10%	58.16%	58.16%	58.16%
FIIs	0.17%	0.17%	0.18%	0.17%	0.17%	0.16%	0.15%	0.15%	0.15%	0.23%	0.16%	0.17%
DIIs	3.09%	0.41%	0.41%	0.62%	0.88%	0.82%	0.75%	0.67%	0.67%	0.67%	0.67%	0.67%
Public	42.19%	44.85%	44.60%	44.40%	44.13%	40.92%	40.99%	41.08%	41.08%	40.94%	41.01%	41.00%
Total Shareholders	26,870	27,202	26,652	26,422	25,717	25,699	25,716	28,943	29,099	28,472	28,189	27,743

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Aug 21, 2024	Multiplier share & stock advi...	Bulk	Sell	154.28	3.86 Cr	2,50,000	0.70
Aug 21, 2024	Multiplier share & stock advi...	Bulk	Buy	154.25	3.55 Cr	2,30,144	0.64
Apr 17, 2024	Ipca laboratories limited	Insider - Promoter	Acquisition	139.50	36.27 Cr	26,00,000	7.85
Jul 12, 2023	Nehal narendra gandhi	Insider - Promoter	Revoke	—	—	1,500	0.00
Jul 12, 2023	Nehal narendra gandhi	Insider - Promoter	Revoke	—	—	4,600	0.01
Jul 12, 2023	Nehal narendra gandhi	Insider - Promoter	Revoke	—	—	900	0.00
Jul 12, 2023	Nehal narendra gandhi	Insider - Promoter	Revoke	—	—	53,000	0.16
Jun 28, 2023	Narendra i. gandhi huf	Insider - Promoter	Disposal	—	—	13,50,000	4.08
Jun 28, 2023	Kunal gandhi	Insider - Promoter & Director	Acquisition	—	—	13,50,000	4.07
Jun 02, 2023	Quant mutual fund quant small...	Bulk	Sell	101.93	1.53 Cr	1,50,000	0.42

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	23	28	33	28	30	41	34	33	33	37
Expenses	20	24	26	26	26	36	29	29	29	39
Operating Profit	2.65	4.18	6.86	2.03	3.71	4.95	5.19	4.09	3.69	-2.54
OPM %	11.58	14.93	21.07	7.31	12.32	12.03	15.36	12.23	11.17	-6.93
Other Income	0.38	-0.18	0.54	0.31	0.56	0.03	0.83	0.82	0.63	1.09
Interest	1.35	1.19	1.28	1.07	0.65	0.54	0.61	0.47	0.85	0.79
Depreciation	3.47	3.59	2.84	2.90	1.76	1.76	1.83	1.42	2.11	2.15
Profit Before Tax	-1.71	-0.66	3.05	-1.67	2.01	2.86	3.58	3.02	1.35	-4.38
Tax %	-7.60	27.27	41.64	-27.54	28.36	26.57	24.30	32.78	26.67	26.71
Net Profit	-1.85	-0.49	1.78	-2.13	1.44	2.10	2.71	2.03	1.00	-3.21
EPS in Rs	-0.53	-0.14	0.49	-3.55	0.40	0.58	0.75	0.49	0.25	-0.94

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	117	61	71	61	86	194	93	111	138	141
Expenses	87	63	73	65	67	93	76	95	121	124
Operating Profit	29	-2.74	-1.90	-3.67	20	101	17	16	18	18
OPM %	25.19	-4.52	-2.68	-5.97	22.82	52.12	18.09	14.13	12.95	12.67
Other Income	-1.90	4.37	0.95	-30	0.43	-4.42	-3.99	1.04	2.23	2.31
Interest	19	9.58	7.17	20	26	20	12	4.89	2.27	2.47
Depreciation	10	11	7.31	8.01	8.32	17	14	13	6.77	7.12
Profit Before Tax	-8.10	-20	-15	-62	-14	59	-13	-0.93	11	11
Tax %	18.59	5.19	58.82	-1.20	28.66	35.11	0.14	-180.63	28.69	27.47
Net Profit	-6.60	-19	-6.35	-63	-10	38	-13	-2.62	7.93	7.84
EPS in Rs	-1.35	—	—	-18.02	-3.26	10.89	-3.78	-3.73	2.22	0.55
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	22	22	28	28	29	29	29	31	33	—
Reserves	22	16	21	15	-43	-54	-15	15	35	68
Borrowings	86	86	51	96	141	163	130	75	59	39
Other Liabilities	111	128	129	77	74	53	42	31	30	69
Total Liabilities	242	252	229	216	200	190	186	152	157	176
Fixed Assets	104	133	116	108	105	98	94	68	58	85
CWIP	30	24	28	31	28	26	18	16	23	1.20
Investments	0.39	0.26	0.23	0.02	0.02	0.02	0.02	0.05	0.09	0.04
Other Assets	107	94	85	77	68	66	74	67	76	90
Total Assets	242	252	229	216	200	190	186	152	157	176

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	12	31	11	27	5.32	8.81	79	8.95	1.77	1.90
Cash from Investing Activity	17	-13	-3.17	-3.97	-0.11	-0.16	-6.17	7.35	-9.49	-12
Cash from Financing Activity	-30	-19	-10	-23	3.38	-12	-63	-22	1.95	5.29
Net Cash Flow	-0.96	-0.43	-2.69	-0.72	8.60	-3.15	9.90	-5.34	-5.76	-4.60

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
TLL	300.00	351 Cr	19.63	4.19	0.00	22.08	17.36	7.60
ZIMLAB	71.00	346 Cr	52.62	1.38	0.00	2.62	6.18	1.41
BROOKS	97.00	287 Cr	20.58	2.48	0.00	12.08	12.32	9.98
LYKALABS	77.30	276 Cr	135.61	2.73	0.00	2.03	4.68	1.50
AMBASARABH	29.09	223 Cr	14.26	1.51	0.00	10.60	10.22	3.70
SYSCHEM	48.55	210 Cr	46.49	2.22	0.00	4.78	5.68	2.49
NATCAPSUQ	186.00	192 Cr	—	0.85	0.00	-4.87	-1.11	-2.84

Overview

Detailed Summary

Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products.

The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India.

Post-2016, Lyka merged its subsidiaries, bolstering its focus on domestic markets and ethical products.

Significant equity acquisition by IPCA and partners in 2021-22 established them as joint promoters, signaling strategic alignment.

In 2023, Lyka acquired the animal healthcare business of Agilis Healthcare, enhancing its veterinary portfolio.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

276 Cr

Volatility

Moderate Risk

P/E Ratio

135.6

Industry P/E

30.8

PEG Ratio

0.3

P/B Ratio

2.7

52W High

167.10

52W Low

73.56

Sales CAGR

24.56%

-6.42%

27.02%

10Y

9.25%

Profit CAGR

402.67%

-40.92%

—

10Y

6.12%

ROE

TTM

2.03%

-3.54%

9.59%

10Y

-17.08%

ROCE

TTM

4.68%

4.37%

18.05%

10Y

7.03%

Lyka Labs Ltd

Lyka Labs Ltd

LYKALABS

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Technicals

Forecasts

Shareholdings

Shareholding History

Market Transactions

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Documents

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Lyka Labs Ltd

LYKALABS

AI Mode

Projection

Peers

Price Chart Comparison

Announcements

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist